Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Treatment Courses of the 6 Patients Receiving HTx for primary cardiac sarcomas in Our Institution

From: Survival after heart transplantation for non-metastatic primary cardiac sarcoma

Age/Sex Histology (Grade) Tumor Sites Operations before HTX, Interval (mo) Multimodal Therapies Tumor Relapse (mo) Outcome Survival (mo)
63/M Synovial Sarcoma (G3) LV, RV Partial resection, 7 NT(pre-), XRT to metastasis Lung (1) D, 5
48/M Angiosarcoma (G3) RA, RV Biopsy, 3 IAP(post-op) Liver, Chest (4), D, 5
27/F Angiosarcoma (G3) RA, RV Biopsy, 2 IAP(post-op) Lung (12) D, 15
49/F Undifferentiated Pleomorphic Sarcoma (G3) RA, LA, LV Partial resection, 5 Re-HTx at 36mo PV (33), Liver, PV (40) D, 43
49/F Undifferentiated Pleomorphic Sarcoma (G2) LA, LV Partial resection, 9 No - Da, 18
61/M Myxoid Liposarcoma, (G2) RV Partial resection, 3 No - Alive, 93
  1. aComplicated by one episode of acute rejection, heart failure unrelated to tumor was the reason of death
  2. D death, F female, HT, heart transplantation, IAP ifosfamide/doxorubicin/cisplatin, LA left atrium, LV left ventricular, M male, NT vinorelbine/cisplatin, RA right atrium, RV right ventricular, XRT radiation therapy